



Engineered Nanomaterials for Diagnosis, Prevention and Therapy

Guest Editor:

Dr. Aniruddha Adhikari

Department of Chemical and
Biomolecular Engineering,
University of California at Los
Angeles (UCLA), Los Angeles, CA,
USA

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Biologically active engineered nanomaterials are indispensable tools in healthcare research, bringing innovative approaches to diagnosis, treatment, and disease management, and offering a transformative outlook. Their precise and targeted therapeutic capabilities hold promise for mitigating several unmet diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Notably, several of these nanomaterials can traverse biological barriers, such as the blood–brain barrier, enabling the treatment of previously inaccessible diseases and conditions. In addition, engineered nanomaterials can significantly contribute to diagnostics by enabling the development of highly sensitive and specific nano-based biosensors, imaging agents, and diagnostic tools. Therefore, the potential of engineered nanomaterials to enhance drug delivery, diagnostics, and personalized medicine positions this topic as a pivotal field for advancing healthcare solutions. This Special Issue of Biomedicine is focused on the recent advances, methods, and approaches in preparing engineered nanomaterials and their applications in the diagnosis, prevention and therapy of diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)